Correction: MiR-34a-5p promotes the multi-drug resistance of osteosarcoma by targeting the CD117 gene.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. The antagonistic effect of FTO on METTL14 promotes AKT3 mJournal of cancer research and clinical oncology · 2024
   Article
2. LAMTOR5-AS1 regulates chemotherapy-induced oxidative stress by controlling the expression level and transcriptional activity of NRF2 in osteosarcoma cells.Cell death & disease · 2021
   Article
3. The DNA methylation-regulated MCTP1 activates the drug-resistance of esophageal cancer cells.Aging · 2021
   Article
4. Microenvironment-Induced Non-sporadic Expression of the AXL and cKIT Receptors Are Related to Epithelial Plasticity and Drug Resistance.Frontiers in cell and developmental biology · 2018
   Article

Corrections and comments

• Erratum for
  MiR-34a-5p promotes the multi-drug resistance of osteosarcoma by targeting the CD117 gene.2016

Authors and funding

7 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract